Mulon Luo is a counsel in the firm’s Technology Companies & Life Sciences Group. Ms. Luo represents private and public companies in a range of industries including biotechnology, medical devices, diagnostics, healthcare information technology, Internet, and software. She regularly counsels clients on start-up and formation matters, venture capital financings, mergers and acquisitions, public offerings, SEC reporting and compliance, and other corporate, strategic, and corporate finance matters. She also has experience advising clients in the life sciences sector on technology transactions and commercial contract matters. She joined Goodwin in 2008, and has had the unique opportunity to have practiced in the firm’s Boston, New York and Washington D.C. offices.

Experience

ERFAHRUNG

工作经历

Some of Ms. Luo’s representative matters include:

  • 5AM Ventures in its investment in a computational genomics company focused on identifying inherited disease risk in future generations and in a digital therapeutics company for enhanced clinical outcomes
  • A healthcare venture firm in multiple rounds of investment in an oral healthcare company that develops, acquires and commercializes oral health care technologies
  • Action Pharma, a privately owned Danish biotech company, in its $110 million sale to Abbott Laboratories
  • Axcella Health, a biotechnology company pioneering first-in-class medicines for serious conditions linked to amino acid imbalances, in multiple financing rounds, including its $42.5 million Series D financing
  • Endeca Technologies, a provider of unstructured data management, web commerce and business intelligence solutions, in its sale to Oracle
  • ExtendMedia, a provider of software-based content management systems, in its sale to Cisco
  • Lycera Corp. in its collaboration and buyout option transaction with Celgene Corporation with a value of up to $105 million
  • Moderna Therapeutics, a biotechnology company that researches and develops protein therapies based on mRNA technology, in multiple financing rounds, including its $110 million Series D financing and $500 million Series E financing
  • Ra Pharmaceuticals, a clinical stage biopharma developing a treatment for PNH, a rare orphan disease, in its $8 million Series A financing and $58.5 million Series B financing
  • The underwriters in the $50.9 million initial public offering, and subsequent follow-on offering, of a specialty pharmaceutical company focusing on the development and commercialization of products for treating central nervous system disorders
  • The underwriters in the $58 million follow-on offering of an international pharmaceutical company focusing on the development and commercialization of ancillary hemodialysis products

In The News

MELDUNGEN

在新闻中

Credentials

WERDEGANG

专业资格

Education

J.D., 2008
Boston University School of Law

(cum laude)

B.A., 2003
Yale University

Admissions

Bar

Massachusetts
New York
District of Columbia
Get In Touch
KONTAKT
Get In Touch
联系我们
Our clients rely on us for world-class advisory services, counsel on complex transactional work and high-stakes litigation. Specializing in matters involving the financial, life sciences, private equity, real estate, and technology industries, we use a collaborative, cross-disciplinary approach to resolve our clients’ most challenging issues. To find out more, please contact us.
Unsere Kunden verlassen sich auf uns für erstklassige Beratungsdienste, beraten über komplexe Transaktionsarbeiten und High-Stakes-Prozesse. Spezialisiert auf Angelegenheiten der Finanz-, Life-Sciences-, Private-Equity-, Immobilien-und Technologie-Industrie, verwenden wir eine kooperative, interdisziplinäre Ansatz zur Lösung unserer Kunden am schwierigsten Fragen. Um mehr zu erfahren, kontaktieren Sie uns bitte.

客户信赖我们世界一流的咨询服务,希望获得针对复杂事务性工作与高风险诉讼的建议。我们通过协作式、跨领域的工作方法来解决客户最棘手的问题,涵盖金融、生命科学、私募股权、不动产和技术等多个行业。如需更多信息,请与我们联系。

Search Other Lawyers
ANWALTSSUCHE
搜寻其他律师